Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Mar;66(2):111-2, 114-8, 120.
doi: 10.1007/s00393-007-0150-z.

[Immunization in children and adolescents with rheumatic diseases]

[Article in German]
Affiliations
Review

[Immunization in children and adolescents with rheumatic diseases]

[Article in German]
K Minden et al. Z Rheumatol. 2007 Mar.

Abstract

Vaccinations represent a special problem in children and adolescents with inflammatory rheumatic diseases. There are very limited data on the safety and efficacy of vaccines in these patients, and guidelines for immunization are missing. The immunosuppressive therapy often necessary for these patients gives rise to additional uncertainty. In addition, many colleagues consider vaccination to increase the risk of relapse of the rheumatic illness. As a consequence, there are substantial variations in practicing vaccination in these patients, resulting in insufficient vaccination coverage rates. For example, every third patient with juvenile idiopathic arthritis is incompletely vaccinated; this even includes toxoid vaccines for tetanus and diphtheria. The benefit of vaccinations, which far outweighs their potential risks, is well recognized even in patients with autoimmune diseases. These patients in particular require a special protection from infections due to their immunosuppressive therapies. Therefore, children and adolescents with rheumatic diseases should be immunized according to the Standing Immunization Commission of the Robert Koch Institute recommendations whenever possible. However, the time of vaccination must be carefully selected, taking disease activity and treatment into account.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Clin Exp Rheumatol. 2004 Nov-Dec;22(6):749-55 - PubMed
    1. Rheumatology (Oxford). 2007 Apr;46(4):608-11 - PubMed
    1. Ann Rheum Dis. 1986 Feb;45(2):110-4 - PubMed
    1. Clin Exp Rheumatol. 2002 Nov-Dec;20(6):767-71 - PubMed
    1. Rheumatology (Oxford). 2002 Aug;41(8):937-41 - PubMed

MeSH terms

Substances

LinkOut - more resources